Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.30 USD
Change Today -0.0001 / -0.03%
Volume 43.1K
RGDX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

response genetics inc (RGDX) Snapshot

Open
$0.30
Previous Close
$0.30
Day High
$0.30
Day Low
$0.28
52 Week High
05/6/14 - $1.25
52 Week Low
04/1/15 - $0.18
Market Cap
11.6M
Average Volume 10 Days
116.2K
EPS TTM
$-0.31
Shares Outstanding
38.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESPONSE GENETICS INC (RGDX)

Related News

No related news articles were found.

response genetics inc (RGDX) Related Businessweek News

No Related Businessweek News Found

response genetics inc (RGDX) Details

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

96 Employees
Last Reported Date: 03/31/15
Founded in 1999

response genetics inc (RGDX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.3K
Chief Financial Officer
Total Annual Compensation: $296.7K
Compensation as of Fiscal Year 2013.

response genetics inc (RGDX) Key Developments

Response Genetics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014

Response Genetics Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net revenue of $4,079,167 against $4,770,977 a year ago. Operating loss was $3,067,785 against $3,151,621 a year ago. Net loss was $3,412,062 against $3,180,931 a year ago. Basic and diluted loss per share was $0.09 against $0.09 a year ago. For the year, the company reported net revenue of $16,720,327 against $19,801,359 a year ago. Operating loss was $13,007,588 against $7,945,805 a year ago. Net loss was $13,699,362 against $8,020,515 a year ago. Basic and diluted loss per share was $0.35 against $0.24 a year ago. The company's net loss increased primarily due to the nature and timing of the decrease in pharmaceutical revenues and increased expenses.

Response Genetics, Inc Announces Resignation of Stephanie H. Astrow as Vice President, Research and Development

Response Genetics Inc. announced on March 16, 2015, Stephanie H. Astrow, PhD, Vice President, Research and Development of the company. She will resign as an officer and employee of the company to pursue other interests, effective March 25, 2015.

Response Genetics, Inc to Report Q4, 2014 Results on Mar 31, 2015

Response Genetics, Inc announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGDX:US $0.30 USD -0.0001

RGDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $9.22 USD +0.05
NanoString Technologies Inc $12.67 USD +0.73
Psychemedics Corp $16.09 USD +0.58
Rosetta Genomics Ltd $3.48 USD -0.21
Veracyte Inc $8.97 USD -0.18
View Industry Companies
 

Industry Analysis

RGDX

Industry Average

Valuation RGDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE GENETICS INC, please visit www.responsegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.